Osl asx

Morningstar Investor users sign in here. Skip to Content.

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board. Corporate governance.

Osl asx

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech. Show more Markets link Markets. Show more Opinion link Opinion. Show more Personal Finance link Personal Finance. Actions Add to watchlist Add to portfolio Add an alert. Health Care Pharmaceuticals and Biotechnology. Price AUD 0. Use our equities screener to discover other potential opportunities.

Investment products.

OncoSil Medical Limited. Is OSL undervalued compared to its fair value, analyst forecasts and its price relative to the market? For this estimate we use a Discounted Cash Flow model. This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors. What is the analyst month forecast and do we have any statistical confidence in the consensus price target?

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board. Corporate governance.

Osl asx

OncoSil Medical Ltd is an Australia-based medical device company seeking to advance radiation for cancer patients. The Company is focused on the development and commercialization of its lead product candidate, OncoSil localized radiation therapy, for the treatment of pancreatic and distal cholangiocarcinoma. OncoSil is a single-use brachytherapy device that has received breakthrough device designation in the European Union, the United Kingdom, and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy. OncoSil comprises phosphorous microparticles suspended in a specially formulated diluent. OncoSil is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. Financial Times Close.

Honda hpd package

All rights reserved. Market resources. Issuer Services. Renzo DiCarlo Head of Transformation. Here we also display the market cap and forecasted growth for additional consideration. Has less than 1 year of cash runway. New major risk - Market cap size Oct This is why it is important that you get to know the people behind the logo. Personal Finance. DLT as a Service. Investor resource home. Investment options.

You can access current holdings, dividend information and update personal information, e.

Debt securities. For Individual Investors. OncoSil Medical Limited. Investment options. Upcoming Dividends. Issuer Services. Nov Clearing and settlement services. Morningstar Indexes. To access these valuable tools and see the full perspective, subscribe now.